Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Aneurysmal Disease Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Ferritin and Iron Burden in SAH sIRB

NCT03754725
View directory record Official record
Conditions
SAH, Dementia
Interventions
Deferiprone pill, placebo, Montreal Cognitive Assessment
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Iowa City, Iowa • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 1, 2026, 10:37 PM EDT
Recruiting No phase listed Observational

Vascular Lab Resource (VLR) Biorepository

NCT05628948
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Disease, Peripheral Artery Disease, Carotid Disease, Aneurysmal Disease, Venous Disease, Thrombosis, Lymphedema, Lipedema, Non-Atherosclerotic Chronic Arterial Occlusive Disease, Vasculitis, Fibromuscular Dysplasia, Arterial Dissection, May-Thurner Syndrome, Thoracic Outlet Syndrome, Vasospasm
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2019 – 2031
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 1, 2026, 10:37 PM EDT
Completed Early Phase 1 Interventional

Pterygopalatine Fossa Block in Aneurysmal Subarachnoid Hemorrhage

NCT05925478
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
Ptergyopalatine Fossa Block, Bupivacaine 0.25% Injectable Solution
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 1, 2026, 10:37 PM EDT
Recruiting Phase 4 Interventional

Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage

NCT07116408
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage (aSAH), Headache
Interventions
Lidocaine (drug), Tx 360
Drug · Device
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 1, 2026, 10:37 PM EDT
Recruiting Phase 1 Interventional

Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

NCT06863480
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia
Interventions
tocilizumab-aazg (TYENNE)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 1, 2026, 10:37 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

NCT05995405
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Interventions
GTX-104, Nimotop 30 MG Oral Capsule
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 1, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

BLOCK-SAH - PPF-Block for Post-SAH Headache

NCT06008795
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Headache
Interventions
Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone, Placebo Pteryogpalatine Fossa Injection
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Gainesville, Florida • Miami, Florida • Stuart, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 1, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

NCT00978822
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Hypertension
Interventions
Clevidipine butyrate injectable emulsion
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 1, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

NCT02712788
View directory record Official record
Conditions
Cerebral Vasospasm
Interventions
Milrinone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 1, 2026, 10:37 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:

NCT02432157
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm, Hyponatremia
Interventions
HTS 3%, Standard fluid management
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 1, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Balloon Prophylaxis of Aneurysmal Vasospasm

NCT00282893
View directory record Official record
Conditions
Aneurysm, Vasospasm
Interventions
transluminal ballooning, currently existing therapies for the treatment of vasospasm
Procedure · Other
Lead sponsor
University of California, Davis
Other
Eligibility
17 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Sacramento, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 1, 2026, 10:37 PM EDT
Not yet recruiting Phase 4 Interventional

Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage

NCT07246629
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Normal Saline, Nicardipine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 1, 2026, 10:37 PM EDT
Recruiting No phase listed Observational

Augmented Renal Clearance in Neurocritical Care

NCT07410624
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), Status Epilepticus, Bacterial Meningitis, Augmented Renal Clearance (ARC), Subarachnoid Hemorrhage, Aneurysmal, Ischemic Stroke, Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years to 85 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Lexington, Kentucky • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 1, 2026, 10:37 PM EDT
Not yet recruiting No phase listed Observational

Continuous Assessment of Brain Blood Perfusion in Subarachnoid Hemorrhage Patients Using Near-Infrared Spectroscopy (NIRS)

NCT06932640
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
- Non-Invasive Near-infrared Spectroscopy (NIRS) device (HEM1 with Foresight Elite Sensor)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 1, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Nicardipine to Treat Cerebral Vasospasm

NCT01810302
View directory record Official record
Conditions
Cerebral Vasospasm
Interventions
Nicardipine hydrochloride, Preservative-free normal saline
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 1, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT04566991
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Deferoxamine, Placebo
Drug
Lead sponsor
Aditya S. Pandey, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 1, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT00111085
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
10
States / cities
Peoria, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 1, 2026, 10:37 PM EDT
Withdrawn Phase 4 Interventional

Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study

NCT01935908
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Seizures
Interventions
levetiracetam
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 1, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

NCT03585270
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 1, 2026, 10:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

NCT03691727
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
tirofiban hydrochloride (AGGRASTAT®), MRI, Neurological Exam, Questionnaires, Vital Signs, Standard of Care Treatment
Drug · Diagnostic Test · Behavioral + 1 more
Lead sponsor
David Hasan
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 1, 2026, 10:37 PM EDT
Completed Phase 3 Interventional

Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial

NCT00731627
View directory record Official record
Conditions
Subarachnoid Haemorrhage
Interventions
placebo, simvastatin
Drug
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Other
Eligibility
18 Years to 65 Years
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 1, 2026, 10:37 PM EDT
Recruiting Not applicable Interventional

The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage

NCT07131696
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Vasospasm, Cerebral, Transcutaneous Vagal Nerve Stimulation (tVNS), Endovascular Treatment
Interventions
Transcutaneous Vagal Nerve Stimulation
Device
Lead sponsor
Marshall Holland
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 1, 2026, 10:37 PM EDT
Suspended Not applicable Interventional

The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage

NCT06443177
View directory record Official record
Conditions
Vasospasm, Cerebral, Aneurysmal Subarachnoid Hemorrhage
Interventions
Vectris trial leads and stimulation, Sham
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 1, 2026, 10:37 PM EDT
Completed Phase 1 Interventional

Cervical Spinal Cord Stimulation for the Prevention of Cerebral Vasospasm

NCT00766844
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
spinal cord stimulation
Device
Lead sponsor
Konstantin V. Slavin
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 1, 2026, 10:37 PM EDT